{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "VEEV",
  "name": "Veeva Systems Inc.",
  "url": "https://frontierpicks.com/dossiers/VEEV/",
  "json_url": "https://frontierpicks.com/dossiers/VEEV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "Veeva Systems’ recovery rests on Vault CRM adoption overcoming Salesforce competition, supported by 16% subscription growth reported on 2026-08-26. A daily close above the September 18 reference high of $306.22 would complete the recovery case; a daily close below $245 would invalidate it.",
  "invalidation_trigger": "A daily close below $245 breaks the pre-earnings reference area and ends the recovery thesis; fiscal third-quarter revenue below the $932 million guidance floor or a reduction in the $3,682–3,687 million annual revenue outlook would also contradict its operating premise.",
  "catalyst_date": "2026-09-24",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "ai-enterprise-software",
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends January 31: \"FY2027\" spans Feb 2026–Jan 2027, so fiscal and calendar labels differ by nearly a full year.",
    "Veeva is a Delaware public benefit corporation, so the board is charged with balancing stakeholder interests alongside shareholder return.",
    "Guidance is issued on a non-GAAP footing for operating income; GAAP operating margin was 29.6% in Q2 FY2027 versus 44.8% non-GAAP."
  ],
  "body_markdown": "## Current Thesis\n\nVeeva Systems’ post-earnings recovery rests on Vault customer relationship management (CRM) adoption overcoming Salesforce competition; a daily close above the September 18 reference high of $306.22 would complete the recovery case, while a daily close below $245 would invalidate it. The operating evidence remains the 2026-08-26 report: fiscal second-quarter revenue of $928.0 million, subscription growth of 16% year over year and 12 top-20 biopharma commitments to Vault CRM.\n\nThe narrative is maturing — the analyst repricing cluster dates to 2026-08-27–28, while the 2026-09-18 close of $260.21 remained 15.0% below the supplied 52-week high. This is an inference about the recovery’s stage, not a measurement of investor flows. Evidence supports low conviction in a return above that high before the $245 invalidation: the supplied September 18 relative strength index over 14 periods was 35.4 despite a three-month price increase of 69.9%.\n\nThe refresh adds continued analyst support beyond the August cluster: TipRanks records Wells Fargo’s Stan Berenshteyn raising his target to $330 on 2026-09-09 and TD Cowen reiterating $283 on 2026-09-15. Those are third-party valuations, not evidence that customers have migrated or revenue has accelerated. [TipRanks analyst history](https://www.tipranks.com/stocks/veev/forecast)\n\n## Bull Case\n\n- **Subscription growth supports the recovery.** Veeva’s 2026-08-26 results reported fiscal second-quarter subscription revenue of $766.8 million, up 16% year over year, alongside total revenue of $928.0 million, up 18%. The inference that migration supports recurring growth would weaken if the next report showed subscription growth below 16%.\n- **Large customers committed to Vault.** The 2026-08-26 prepared remarks reported more than 180 live Vault CRM customers and 12 top-20 biopharma commitments after two additional August commitments. Further adoption remains a hypothesis; an unchanged commitment count at the next results release would leave it unconfirmed.\n- **Management raised the annual outlook.** On 2026-08-26, Veeva raised fiscal 2027 revenue guidance to $3,682–3,687 million and guided fiscal third-quarter revenue to $932–935 million. A subsequent reduction in that annual revenue range would contradict the operating improvement behind the recovery.\n\n## Bear Case\n\n- **Competitive attention survived the earnings beat.** Salesforce’s 2026-09-15 Life Sciences keynote agenda listed executives from Takeda, AstraZeneca and Fresenius Kabi. Participation establishes competitive visibility; it does not establish a newly awarded CRM contract or a Veeva displacement. A named customer explicitly replacing Veeva with Salesforce would provide materially stronger evidence. [Salesforce session catalog](https://reg.salesforce.com/flow/plus/df26/sessioncatalog/page/catalog/session/1781727001455001liKc)\n- **Revenue mix needs another observation.** In the 2026-08-26 release, subscription growth of 16% trailed total revenue growth of 18%, and professional services revenue was $161.2 million. Those figures alone do not establish that migration work is temporary or that subscription demand is weakening; a subsequent subscription slowdown would make the concern observable.\n- **Adjusted profitability exceeds reported profitability.** The 2026-08-26 results showed a 44.8% operating margin under management’s non-GAAP measure, versus 29.6% under generally accepted accounting principles (GAAP). The reported margin matters when assessing how much of the earnings recovery depends on adjustments.\n\n## Setup & Price Structure\n\nThe supplied adjusted daily series records a $260.21 close on 2026-09-18, a 52-week high of $306.22 and a three-month gain of 69.9%. Its 14-period relative strength index of 35.4 describes weaker recent momentum than the three-month change alone suggests. No moving-average value or volume series is available, so a rising-average support claim or accumulation claim is unsupported.\n\nThe $245 thesis boundary remains the published research reference associated with the 2026-08-26 pre-earnings area. The September 18 close remains above it; a daily close below $245 would break the recovery structure. A daily close above the supplied $306.22 reference high would satisfy the price outcome, rather than merely repeat an analyst valuation.\n\nCoverage clustering is observable: the supplied Benzinga record contains nine target increases on 2026-08-27–28 and a general-audience historical-return article on 2026-08-31. Wells Fargo’s September 9 increase extends that attention into September. Neither the article cluster nor the analyst updates measures retail ownership, short interest or institutional demand; the evidence is insufficient to establish crowding. [September analyst updates](https://www.tipranks.com/stocks/veev/forecast)\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-24 — Singapore Commercial Summit.** Veeva’s published Asia-Pacific agenda includes sessions on its commercial products and Vault CRM. Customer disclosures could update the adoption evidence, but the scheduled meeting itself does not resolve revenue conversion. [Veeva summit agenda](https://www.veeva.com/ap/events/commercial-summit-singapore/agenda/)\n- **2026-10-20 — R&D and Quality Summit opens.** Veeva lists its Boston research and development (R&D) and Quality Summit for 2026-10-20–21. The opening falls within the next 30 days; the event offers a venue for customer and product updates outside CRM, without constituting an earnings release. [Veeva summit overview](https://www.veeva.com/events/rd-summit/)\n- **~2026-12-02, estimated — Fiscal third-quarter results.** This remains an unconfirmed reporting estimate. The later financial test matters because the 2026-08-26 guidance specified $932–935 million of quarterly revenue; revenue below $932 million or a reduction in the annual outlook would contradict the operating recovery.\n\nThe 2026-09-15–17 Dreamforce conference has elapsed. Its published Life Sciences agenda identifies speakers, but does not establish whether the previously specified new-customer invalidation occurred; the absence of a verified contract disclosure cannot be treated as competitive clearance. [Salesforce conference agenda](https://reg.salesforce.com/flow/plus/df26/sessioncatalog/page/catalog/session/1781727001455001liKc)\n\n## What Would Change Our Mind\n\nLoss of the pre-earnings reference area would end the price recovery thesis: a daily close below $245 is the gradeable condition. Separately, the next reported quarter falling below the $932 million revenue floor guided on 2026-08-26, or management reducing its $3,682–3,687 million annual revenue outlook, would contradict the operating premise even if price remained above that boundary.\n\nEvidence for renewed acceleration would require more than a conference appearance or another analyst target. A Vault CRM commitment count above the 12 reported on 2026-08-26, accompanied by subscription growth at least matching that quarter’s 16%, would strengthen the case; unchanged commitments or slower subscription growth would fail that test.\n\n## Correlation Notes\n\nThis remains a single-company setup: the 2026-09-20 coverage context assigns Veeva to no active theme cluster. The supplied 2026-08-27–28 market coverage placed its earnings move alongside advances in other technology shares, but those observations are too few to establish a correlation or a dependable group driver.\n\nArtificial-intelligence exposure remains a thematic interpretation rather than a separately measured earnings contribution: the September 24 commercial agenda includes Vault AI, while the financial evidence used here reports subscription and services revenue. A claim that AI is driving incremental revenue would require a company disclosure connecting adoption to revenue; the available figures do not establish that link. [Veeva commercial agenda](https://www.veeva.com/ap/events/commercial-summit-singapore/agenda/)",
  "first_seen": "2026-09-01",
  "last_analyzed": "2026-09-19T22:27:49+00:00",
  "last_synthesized": "2026-09-19",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}